2013 a banner year stock prices 40 to 50. Congratulations MRK.

2013 was a a great year for Ken Frasier and his team. They were successful in enhancing Stockholder value by over 25 %. Stock price of 50. So bonus and pay increases this year will be bountiful to MRK executives in 2014. This was delivered by executing aggressive cost controls.

Next year they have to grow the company by launching new products not sure they have the team or the products to achieve this goal.

 

12 to 14 new product launches in 2014.

 

Nice try at smoke and mirrors, but Merck stock underperformed vs. every major market index, given the record-breaking year for the stock market. In 2013, S&P 500 was up 30%, NASDAQ was up 38%! MRK also trailed the Dow Jones average, which it is part of. As an investor, you would have done better with any index out there compared to MRK.

MRK stock price is propped up by share buybacks, a short-term fix for an otherwise dismal outlook. Calling 2013 a banner year for this company is like calling 1912 a banner year for the Titanic. So to sum it up, you're a douche.

 

Glad to have a job but geeez...what about the little guy? The one's hangin' on with the whopper .5%-1.0% increases. It's those poor notches on the totum pole of fame and glory who've been sweatin' it out.... our bills are the only thing bountiful. What's in your wallet?

 

And congratulations to the thousands of former employees, too. And that empty, fruitless pipeline is really impressive. And how about all of those buildings we've shuddered and sold? Good work there! And let's not forget the steadily falling revenue. I don't think that's gonna hurt our stock price down the road, do you? When the stock price is $20, I'll be looking for your words of congratulations then, you short-sighted moron.

Hey, what's 40,000 shit-canned employees, an empty pipeline, neighborhoods of shuddered buildings and a remaining pack of idiots like the OP when you have a market run-up to celebrate?

 

Sad to say that in life too often we meet up with the attitude, "I've got mine. Period." Have seen it in companies, acquaintances, co-workers and on the news every day.....

If you're an honest, true, bona fide good worker in the end you might be in poor shape....
and it's due only to your lack of the right combination of whatever...name, school, network, privilege or these days, some wacky politically driven favoritism of sorts...Heck, the goof offs and incompetents can prosper with the right combination of characteristics...

The real deal is that for most people life is not benevolence and sugar plums....so
we keep on trying harder.....

 

Totally agree.. What was Mrk stock price in 2004...where is it today that is what kind of annual return over 10 years ..dismal

 

There must be job destruction before job creation. Because of a weak school system the r and d jobs need to go overseas. It's the only way to save the company as a whole.

 

We will rise from the rubble, but first there must be rubble. That rubble is Merck and everyones jobs.

Wow, what a positive outlook.

 

Its comforting to know that the Merck brain trust in charge of creating the rubble will also be in charge of the rebuild. Unfortunately they will find that creating something, or even maintaining it, is a hell of a lot easier than creating it. Good luck!

 

"shuddered"..... really?

 

Cut the BS !!! 12-14 product launched in 2014. Really, I am aware of the following, and they are not going to move the needle.


Osteo ? Is the safety data completed ? Will we be able to differentiate vs generics and charge premium ?
Sleep ? No way this is packaged and ready. Drug is DOA due to FDA slamming high dose
Onc PD1 Maybe...It will be 8 months behind Bristol's PD1
Suggamadex....Who cares, this anesthesia hospital brand will be generate chump change

Anything else ??? Please inform, what did I miss ?

 

Huge risk ahead. Ranked 12th out of 16 by Forbes for 2013.

http://www.forbes.com/sites/matthewherper/2013/12/31/grading-pharma-in-2013-16-drug-companies-ranked/

The Rear Guard

12. Merck & Co.

Market capitalization: $143 billion
Stock appreciation: +19.4%
Grade: B-
Oh, Merck, running so hard to stay in place. This time last year its niacin drug for high cholesterol proved toxic and it delayed filing a key osteoporosis pill with the FDA. Then it announced it was replacing Peter Kim, head of R&D. It later announced that it would cut 8,500 jobs. Next year could be tough, too. The study of Vytorin in heart disease that should read out in 2014 is, to put it kindly, high risk.

No wonder Chief Executive Ken Frazier is having trouble regaining Wall Street’s confidence. But he is doing a lot of the right things: replacing Kim with former Amgen R&D honcho Roger Perlmutter; focusing the labs on a few key programs, including its exciting PD-1 antibody for various cancers, which could be a breakout product; expressing a willingness to spin off animal health or do other shareholder-friendly deals. It’s the sense that Merck is making a real shift that saved it from a lower grade, and that could deliver dividends in the new year.

 

I hope whoever wrote this is not in finance or has a helluva sense of sarcasm. One look at the 2013 Forbes Pharma ranking not only puts Merck towards the bottom of enhancing shareholder value but it's competition has beat the day lights out of them in the stock appreciation metric.

Merck is in the BOTTOM of the sector for stock appreciation over the last year.

1. Bristol-Myers Squibb Company

Market capitalization: $87 billion
Stock appreciation: +61.4%
Grade: A+

2. Celgene Corporation

Market cap: $67 billion
Stock appreciation: +107%
Grade: A

3. Biogen Idec

Market Capitalization: $67 billion
Stock appreciation: +92%
Grade: A

4. Gilead Sciences

Market capitalization: $113 billion
Stock appreciation: +100%
Grade: A-

5. AbbVie

Market capitalization: $86 billion
Stock appreciation: +59%
Grade: A-

6. Roche

Market capitalization: $235 billion
Stock appreciation: +32%
Grade: B+

7. Johnson & Johnson

Market capitalization: $261 billion
Stock appreciation: +32%
Grade: B+

8. GlaxoSmithKline

Market capitalization: $126 billion
Stock appreciation: 18.1+
Grade: B+

9. Amgen

Market capitalization: $85 billion
Stock appreciation: +30.8%
Grade: B

10. Pfizer Inc.

Market capitalization: $199 billion
Stock appreciation: +23%
Grade: B

11. Novartis

Market cap: $189 billion
Stock apprecition: +22.5%
Grade: B

12. Merck & Co.

Market capitalization: $143 billion
Stock appreciation: +19.4%
Grade: B-

13. Novo Nordisk

Market capitalization: $75 billion
Stock appreciation: +7.8%
Grade: B-

14. Sanofi

Market capitalization: $135 billion
Stock performance: +7.3%
Grade: B-

15. AstraZeneca

Market capitalization: $73 billion
Stock appreciation: +24.5%
Grade: C+

16. Eli Lilly and Company

Market capitalization: $57 billion
Stock appreciation: +2.4%
Grade: C

 

Take a drive through the old HQ sometime. You'll see Merck's past, present and future. Those of you that think of Merck as "too big to fail" are clueless.

 

Congratulation Ken Mrk hit 53.10....keep it up. Return to investment is the key.

 

This management team is getting their act together!

 

You all have your head in the sand. Merck's stock has gone up solely based on cost saving measures not on new revenues. Anyone with a high school education can research this and know it is a fact!

 

Doesn't matter how just so the numbers add up Mr CPA.

 

Doesn't matter how the numbers add up? Really? The basis for the numbers going up is a farce if the objective is to become a revenue growth company. Why not just fire everybody and sell all the buildings. It puts lots of money in the bank and a tremendous reduction in expenditures.